This study is testing how well two cancer drugs, **nivolumab** and **ipilimumab**, work with or without another drug called **sargramostim** in treating advanced melanoma, a type of skin cancer. Melanoma is "advanced" when it spreads or can't be removed by surgery. The drugs being tested are **immunotherapy** drugs, which help the immune system fight cancer. **Sargramostim** is a colony-stimulating factor that boosts white blood cell production to help fight infections.
Key Points:
- This study lasts up to 2 years with treatment cycles every 3 weeks for 4 cycles and follow-ups every 3 to 6 months after treatment.
- Participants must have stage III-IV melanoma and meet specific health criteria. They should not have certain other medical conditions or have used certain medications recently.
- Eligible participants must not be pregnant or breastfeeding, and they need to use effective birth control methods during the study.
Participants will receive treatments through IV and injections and undergo tests like MRI and CT scans. The study will compare the survival and side effects of using nivolumab and ipilimumab with and without sargramostim.
How understandable was the trial content above?
Hard to understand
Easy to understand